Live Breaking News & Updates on ப்ரோக்ர்யாம் வழிகாட்டல்
Stay updated with breaking news from ப்ரோக்ர்யாம் வழிகாட்டல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
La Nit de la Recerca torna per acostar la ciència a la ciutadania dbalears.cat - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dbalears.cat Daily Mail and Mail on Sunday newspapers.
Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
El 92,5% dels estudiants han aprovat la selectivitat a les Balears dbalears.cat - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dbalears.cat Daily Mail and Mail on Sunday newspapers.
Share this article LEXINGTON, Mass., April 12, 2021 /PRNewswire/ Pulmatrix, Inc. (NASDAQ: PULM), is re-issuing this press release solely to correct inadvertent typographical errors under the heading Updated PUR1800 Program Guidance which incorrectly noted that Pulmatrix plans to initiate a PUR1800 Phase 2 proof-of-concept efficacy study for the treatment of AECOPD in 2021. This study is not expected to commence until 2022 All other data and disclosure remain unchanged. The corrected press release reads in its entirety as follows: LEXINGTON, Mass., April 12, 2021 – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced it will regain full rights to its narrow spectrum kinase inhibitor (NSKI) portfolio, including PUR1800, following Johnsons & Johnson s Enterprise Innovation s decision t ....